BOSTON, Mass. — Corsera Health, Inc., a biotechnology company developing preventive RNAi medicines for cardiovascular health, announced the filing of a clinical trial notification to initiate a Phase 1 study of its lead candidate, COR-1004, in New Zealand. COR-1004 is a novel investigational RNA interference (RNAi) therapy designed to lower low-density lipoprotein cholesterol (LDL-C) by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).
The Phase 1 filing marks the first step in Corsera’s broader preventive RNAi medicine program, which aims to reduce two key drivers of cardiovascular disease—LDL-C and blood pressure—through a single, once-annual treatment. The company plans to begin a Phase 1 trial of its second candidate, COR-2003, which targets angiotensinogen (AGT), in mid-2026.
“At Corsera Health, we are challenging what’s possible for cardiovascular health,” said Rena N. Denoncourt, Chief Operating Officer of Corsera Health. “We see a future where a once-annual RNAi medicine can reduce lifetime risk of heart attacks and strokes – which together remain the number one driver of morbidity and mortality in the world. This filing marks an important milestone for Corsera Health as we bring our lead program into the clinic and move one step closer to a world without cardiovascular disease.”
The Phase 1 trial of COR-1004 will be a randomized, double-blinded, placebo-controlled, single-ascending-dose study in healthy adult volunteers. The primary objective is to evaluate the safety and tolerability of COR-1004, with secondary objectives assessing reductions in plasma PCSK9 and LDL-C levels, along with pharmacokinetic and durability data over a 12-month follow-up period.
COR-1004 represents the first component of Corsera’s dual-target preventive RNAi program, which ultimately seeks to combine PCSK9 and AGT suppression into a single medicine to lower both cholesterol and blood pressure through once-yearly administration.
